



NEWS RELEASE

## SELLAS to Present at the 12th Annual LD Micro Main Event

12/4/2019

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the 12th Annual LD Micro Main Event on Wednesday, December 11, 2019 at 9:00 a.m. PT in Los Angeles, CA.

A live audio webcast of the presentation will be available under "Events & Presentations" in the Investors section of SELLAS' website at [www.sellaslifesciences.com/investors](http://www.sellaslifesciences.com/investors). A replay of the webcast will be available for up to 30 days on SELLAS' website following the presentation.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.

For more information on SELLAS, please visit [www.sellaslifesciences.com](http://www.sellaslifesciences.com).

Investor Contacts

Will O'Connor

Stern Investor Relations, Inc.

212-362-1200

**ir@sellaslife.com**

Investor Relations

SELLAS Life Sciences Group, Inc.

917-438-4353

**info@sellaslife.com**

Source: SELLAS Life Sciences Group